Anti-Entry Activity of Natural Flavonoids against SARS-CoV-2 by Targeting Spike RBD

被引:14
|
作者
Meng, Jie-Ru [1 ]
Liu, Jiazheng [1 ]
Fu, Lu [1 ]
Shu, Tong [2 ]
Yang, Lingzhi [2 ]
Zhang, Xueji [2 ]
Jiang, Zhi-Hong [1 ]
Bai, Li-Ping [1 ]
机构
[1] Macau Univ Sci & Technol, Macau Inst Appl Res Med & Hlth, State Key Lab Qual Res Chinese Med, Guangdong Hong Kong Macao Joint Lab Resp Infect Di, Hong Kong 999078, Guangdong, Peoples R China
[2] Shenzhen Univ, Hlth Sci Ctr, Sch Biomed Engn, Shenzhen 518060, Peoples R China
来源
VIRUSES-BASEL | 2023年 / 15卷 / 01期
基金
中国国家自然科学基金;
关键词
flavonoid; antiviral activity; SARS-CoV-2; structure-activity relationship; viral entry inhibitor; IN-VITRO; COVID-19; INHIBITORS; PLANTS; ACE2;
D O I
10.3390/v15010160
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
COVID-19 is still a global public health concern, and the SARS-CoV-2 mutations require more effective antiviral agents. In this study, the antiviral entry activity of thirty-one flavonoids was systematically evaluated by a SARS-CoV-2 pseudovirus model. Twenty-four flavonoids exhibited antiviral entry activity with IC50 values ranging from 10.27 to 172.63 mu M and SI values ranging from 2.33 to 48.69. The structure-activity relationship of these flavonoids as SARS-CoV-2 entry inhibitors was comprehensively summarized. A subsequent biolayer interferometry assay indicated that flavonoids bind to viral spike RBD to block viral interaction with ACE2 receptor, and a molecular docking study also revealed that flavonols could bind to Pocket 3, the non-mutant regions of SARS-CoV-2 variants, suggesting that flavonols might be also active against virus variants. These natural flavonoids showed very low cytotoxic effects on human normal cell lines. Our findings suggested that natural flavonoids might be potential antiviral entry agents against SARS-CoV-2 via inactivating the viral spike. It is hoped that our study will provide some encouraging evidence for the use of natural flavonoids as disinfectants to prevent viral infections.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Tagged extracellular vesicles with the RBD of the viral spike protein for delivery of antiviral agents against SARS-COV-2 infection
    Fu, Yuxuan
    Xiong, Sidong
    JOURNAL OF CONTROLLED RELEASE, 2021, 335 : 584 - 595
  • [42] In vitro and in vivo validation of the antiviral effect of hCypA against SARS-CoV-2 via binding to the RBD of spike protein
    Shin, Woo-Ri
    Kim, Do -Young
    Kim, Sang Yong
    Ahn, Gna
    Park, Dae-Young
    Min, Jiho
    Ahn, Ji-Young
    Kim, Yang-Hoon
    MOLECULAR THERAPY, 2024, 32 (06) : 1805 - 1816
  • [43] MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes
    Lu, Dongchao
    Chatterjee, Shambhabi
    Xiao, Ke
    Riedel, Isabelle
    Wang, Yibin
    Foo, Roger
    Bar, Christian
    Thum, Thomas
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2020, 148 : 46 - 49
  • [44] Development of a Unique Rapid Test to Detect Antibodies Directed Against an Extended RBD of SARS-CoV-2 Spike Protein
    Brosi, Larissa
    Kuebler, Eric
    Weston, Anna
    Romann, Patrick
    Panikulam, Sherin
    Dirscherl, Lorin
    Gerspach, Michael
    Giegelmann, Cedric
    Dolce, Daniele
    Ueberschlag, Marie-Eve
    Melone, Anna
    Bantleon, Frank, I
    Villiger, Thomas K.
    Gerhold, Christian-B
    CHIMIA, 2021, 75 (05) : 446 - 452
  • [45] Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants
    Rodriguez-Aponte, Sergio A.
    Dalvie, Neil C.
    Wong, Ting Y.
    Johnston, Ryan S.
    Naranjo, Christopher A.
    Bajoria, Sakshi
    Kumru, Ozan S.
    Kaurg, Kawaljit
    Russ, Brynnan P.
    Lee, Katherine S.
    Cyphert, Holly A.
    Barbier, Mariette
    Rao, Harish D.
    Rajurkar, Meghraj P.
    Lothe, Rakesh R.
    Shaligram, Umesh S.
    Batwal, Saurabh
    Chandrasekaran, Rahul
    Nagar, Gaurav
    Kleanthous, Harry
    Biswasj, Sumi
    Bevere, Justin R.
    Joshi, Sangeeta B.
    Volking, David B.
    Damron, F. Heath
    Love, J. Christopher
    VACCINE, 2023, 41 (05) : 1108 - 1118
  • [46] Natural Products with Tandem Anti-inflammatory, Immunomodulatory and Anti-SARS-CoV/2 Effects: A Drug Discovery Perspective against SARS-CoV-2
    Leal da Cunha, Luana N. O.
    Tizziani, Tiago
    Souza, Gabriella B.
    Moreira, Monalisa A.
    Neto, Jose S. S.
    dos Santos, Carlos V. D.
    de Carvalho, Maryelle G.
    Dalmarco, Eduardo M.
    Turqueti, Leonardo B.
    Scotti, Marcus Tullius
    Scotti, Luciana
    de Assis, Francisco F.
    Braga, Antonio Luiz
    Sandjo, Louis Pergaud
    CURRENT MEDICINAL CHEMISTRY, 2022, 29 (14) : 2530 - 2564
  • [47] Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2
    Ge, Shuai
    Lu, Jiayu
    Hou, Yajing
    Lv, Yuexin
    Wang, Cheng
    He, Huaizhen
    VIROLOGY, 2021, 560 : 110 - 115
  • [48] Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization
    Shah, Masaud
    Ahmad, Bilal
    Choi, Sangdun
    Woo, Hyun Goo
    COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2020, 18 : 3402 - 3414
  • [49] Promising Antiviral Activities of Natural Flavonoids against SARS-CoV-2 Targets: Systematic Review
    Kaul, Ridhima
    Paul, Pradipta
    Kumar, Sanjay
    Buesselberg, Dietrich
    Dwivedi, Vivek Dhar
    Chaari, Ali
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (20)
  • [50] In-Silico Design of a Novel Tridecapeptide Targeting Spike Protein of SARS-CoV-2 Variants of Concern
    Rajpoot, Sajjan
    Solanki, Kundan
    Kumar, Ashutosh
    Zhang, Kam Y. J.
    Pullamsetti, Soni Savai
    Savai, Rajkumar
    Faisal, Syed M.
    Pan, Qiuwei
    Baig, Mirza S.
    INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS, 2022, 28 (01)